SynthesisDigestive diseases and sciences2022
Systematic Review with Meta-Analysis: Fecal Microbiota Transplantation for Severe or Fulminant Clostridioides difficile.
Synthesis in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06992453 (Disentangling Microbiome Engraftment by Multi-omics of the Gut Ecosystem During Fecal Transplant), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Disentangling Microbiome Engraftment by Multi-omics of the Gut Ecosystem During Fecal Transplant
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Comparative effectiveness of treatments for recurrentFrontiers in pharmacology · 2024Pooled it
- Food as Friend or Foe: A Decadal Narrative Review of Dietary Patterns as Determinants of Gastrointestinal Pathophysiology and Clinical Outcomes (2015-2025).International journal of molecular sciences · 2026Review
- Review
- Navigating recurrentAntimicrobial stewardship & healthcare epidemiology : ASHE · 2025Article
- What's New and What's Next in Fecal Microbiota Transplantation?Biologics : targets & therapy · 2025Review
- Fecal microbiota transplantation: current challenges and future landscapes.Clinical microbiology reviews · 2024Review
- The gut-brain-metabolic axis: exploring the role of microbiota in insulin resistance and cognitive function.Frontiers in microbiology · 2024Review
- Fecal microbiota transplantation as potential first-line treatment for patients withWorld journal of gastrointestinal surgery · 2023Article
- Article
- The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review.Frontiers in microbiology · 2023Review
- Inflammatory bowel disease andTherapeutic advances in gastroenterology · 2023Review
- Management of Clostridioides difficile infection in adults and challenges in clinical practice: review and comparison of current IDSA/SHEA, ESCMID and ASID guidelines.The Journal of antimicrobial chemotherapy · 2022Review
- The central and biodynamic role of gut microbiota in critically ill patients.Critical care (London, England) · 2022Review
- Global research trends and hotspots of fecal microbiota transplantation: A bibliometric and visualization study.Frontiers in microbiology · 2022Review
- Review
- Review
- Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review.Metabolites · 2021Review
- Microbiota, Bacterial Carbonic Anhydrases, and Modulators of Their Activity: Links to Human Diseases?Mediators of inflammation · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere and fulminant Clostridioides difficile infection (CDI) is associated with significant morbidity and mortality. While fecal microbiota transplantation (FMT) has proved to be a highly effective treatment for recurrent CDI, its efficacy in severe or fulminant CDI remains uncertain.
aimsTo perform a systematic review with meta-analysis evaluating clinical outcomes and safety of FMT in severe and fulminant CDI.
methodsA systemic review with meta-analysis was performed through comprehensive search of Embase, Medline (Ovid), trial registers, and conference abstracts through January 2020. Studies on FMT in severe and fulminant CDI were included. Meta-analysis was done with random effects models given heterogeneity to estimate rates of cure, mortality, and colectomy. Publication bias was assessed using Egger's test.
resultsSixteen studies comprised of one randomized controlled trial, four cohort studies, and eleven case series were analyzed. In total, 676 patients underwent FMT for severe or fulminant CDI. The overall rate of clinical cure after single FMT was 61.3% (95% CI 43.2-78.0%) with 10.9% (95% CI 0.2-30.2%) of patients experiencing major adverse events. The overall pooled colectomy rate after FMT was 8.2% (95% CI 0.1-23.7%) with a pooled all-cause mortality rate after FMT of 15.6% (95% CI 7.8-25.0%).
conclusionLow-quality data support the use of fecal microbiota transplantation in patients with severe and fulminant Clostridioides difficile infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.